IP Library Granted Patent US 8,252,322
Granted Patent B2
US 8,252,322 · App. 10/453,011 · Granted Aug 28, 2012

Delivery system with increased bioavailability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,322
App. No.
10/453,011
Granted
Aug 28, 2012
Kind
B2
Abstract

The present invention is directed to a dry composition which allows delivery of active agents with good bioavailability. These compositions are prepared by emulsifying the active agent using liposome technology known in the art and then encapsulating with a modified starch. The modified starch is prepared by enzymatic hydrolysis of starch after the preparation of a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group. The resultant composition is a dry powder with excellent bioavailability. Further, the composition has good load levels and stability.

Claims (25)

1. A composition in the form of a dry powder comprising an aqueous insoluble active agent encapsulated in a plurality of liposomes, wherein said plurality of liposomes are further encapsulated in a matrix comprising:

a gelatinized starch derivative, wherein the starch derivative is formed by reaction with an alkenyl cyclic dicarboxylic acid anhydride, and

wherein the gelatinized starch derivative has been degraded by at least one enzyme capable of cleaving the 1,4-linkages of the starch molecule from the non-reducing ends to produce mono- or di-saccharides; and

wherein at least 50% of the composition passes through a 0.45 micron cellulose acetate filter.

2. The composition of claim 1 , wherein the starch is degraded to a dextrose equivalent of from about 20 to about 80.

3. The composition of claim 1 , wherein the enzyme is selected from the group consisting of β-amylase, glucoamylase, pullulanase, maltogenase, exo-alpha-1,4-glucosidase, exo-1,4-alpha-D-glucan maltotetrahydrolase, and exo-1,4-alpha-D glucan maltohexahydrolase.

4. The composition of claim 1 , wherein the starch is degraded to a dextrose equivalent of from about 20 to about 50 and the enzyme is β-amylase or glucoamylase.

5. The composition of claim 4 , wherein the starch is degraded to a dextrose equivalent of from about 25 to about 38 and the enzyme is β-amylase.

6. The composition of claim 1 , wherein the starch is gelatinized and has been derivatized by treatment with at least 0.1% of octenyl succinic acid anhydride on a starch dry weight basis.

7. The composition of claim 5 , wherein the starch is gelatinized and has been derivatized by treatment with at least 0.1% of octenyl succinic acid anhydride on a starch dry weight basis.

8. The composition of claim 1 , wherein the active agent is selected from the group consisting of coenzyme Q10, conjugated linoleic acid, omega 3/6 fatty acids (marine oils), saw palmetto, phophatidylcholine (PC), phophatidylserine (PS), lutein esters, phytosterol esters, vitamin A palmitate, vitamin C (ascorbyl palmitate), vitamin E (tocopherol), vitamin E acetate, vitamin K, vitamin A (palmitate), vitamin C (Palmitate), vitamin E blends, beta glucans, green tea, isoflavones, phytosterols, phytostanols, lutein, lycopene, and carotenoids.

9. The composition of claim 1 , wherein the active agent is coenzyme Q10.

10. The composition of claim 6 , wherein the active agent is coenzyme Q10.

11. The composition of claim 7 , wherein the active agent is coenzyme Q10.

12. The composition of claim 1 , wherein the starch is present in an amount of from about 30 to 90%, the active agent is present in an amount of about 0.1 to 30% and the liposomes are present in an amount of about 0.5 to 59.9% by weight.

13. The composition of claim 9 , wherein the starch is present in an amount of from about 30 to 80%, the active agent is present in an amount of about 5.0 to 15% and the liposomes are present in an amount of about 10 to 50% by weight.

14. The composition of claim 1 , wherein at least 65% of the composition passes through a 0.45 micron cellulose acetate filter.

15. A solid dosage form comprising the composition of claim 1 .

16. A solid dosage form comprising the composition of claim 9 .

17. A composition in the form of a dry powder, comprising:

an aqueous insoluble active agent encapsulated in a plurality of liposomes, wherein said liposomes are further encapsulated in a matrix comprising a gelatinized starch derivative,

wherein the starch derivative is formed by reaction with an alkenyl cyclic dicarboxylic acid anhydride, and,

at least one compound selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, and a maltodextrin;

and wherein at least 50% of the composition passes through a 0.45 micron cellulose acetate filter.

18. The composition of claim 17 , wherein the starch is gelatinized and has been derivatized by treatment with at least 0.1% of octenyl succinic acid anhydride on a starch dry weight basis and the active agent is coenzyme Q10.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2012
From: NATIONAL STARCH LLC; BRUNOB II B.V.
To: CORN PRODUCTS DEVELOPMENT, INC.
Reel/Frame 027645/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2008
From: NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION
To: BRUNOB II B.V.
Reel/Frame 021096/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2003
From: TRUBIANO, PAOLO C.; KARRAS, AFAF
To: NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION
Reel/Frame 014150/0322 →